Haemonetics Corp (HAE) 38.44 $HAE
3PEA International and Haemonetics Partner to Integrate PaySign Connect with Haemonetics' Donor Management System
Business Wire - Tue Oct 21, 7:49AM CDT
3PEA International, Inc. (OTCBB:TPNL)(OTCQB:TPNL), a vertically integrated provider of innovative prepaid card programs and processing services for corporate, consumer and government applications, today announced that 3PEA and Haemonetics Corporation (NYSE:HAE) have entered into an agreement whereby 3PEA International will integrate its PaySign(R) Connect prepaid debit card solution with Haemonetics' Donor Management System ("DMS"
. The integration will allow users of the Haemonetics DMS to use the PaySign Connect payment solution for the plasma industry. This partnership will bring together the best of both worlds, the industry leading Haemonetics Donor Management System and 3PEA's PaySign(R) Connect, an intuitive, easy-to-use, fully tokenized payment system tailored to the unique requirements of the plasma collection industry.
HAE: 38.44 (+0.78)
Haemonetics Sets Date for Second Quarter Fiscal Year 2015 Earnings Release: November 3, 2014
PR Newswire - Mon Oct 06, 3:00PM CDT
Haemonetics Corporation (NYSE:HAE) will announce its earnings for the second quarter of its fiscal year 2015 on November 3, 2014 in a pre-market press release. The Company will host a webcast to discuss and answer questions about the press release at 8:00 am eastern time on November 3, 2014.
HAE: 38.44 (+0.78)
Perrigo Sells Some Assets to Imago Pharmaceuticals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 3:45PM CDT
Perrigo (PRGO) has out licensed some of its early-stage assets.
BIIB: 321.00 (+5.94), PRGO: 161.33 (+6.33), ABAX: 51.53 (+1.89), HAE: 38.44 (+0.78)
Walgreens Earnings in Line, Alliance Boots Shows Synergy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 9:45AM CDT
Walgreen Co. (WAG) reported adjusted net earnings of 74 cents per share in the fourth quarter of fiscal 2014.
ABAX: 51.53 (+1.89), HAE: 38.44 (+0.78), CVS: 85.55 (+0.36), WAG: 62.96 (+0.13)
Data Intensity Fortifies Track Record of Success in Oracle EBS R12 Implementations and Upgrades
PR Newswire - Tue Sep 23, 8:30AM CDT
Data Intensity, the industry leader in managed and cloud services for Oracle technologies and applications, today announced a significant milestone in the company's rich history of driving implementations and upgrades to Oracle E-Business Suite (EBS) Release 12 (R12) for its global customers. Data Intensity is celebrating the inception of its dedicated application engineering team, established five years ago this month to address the market need for expertise in planning, managing and executing on the most complex Oracle projects. The team also recently completed one of its most challenging upgrades to date for Haemonetics Corp, a global healthcare company that provides innovative blood management solutions. This deployment was one of ten R12 projects Data Intensity has delivered successfully this year, and the most recent of the 70+ R12-focused engagements the team has completed since the technology's release in 2007.
HAE: 38.44 (+0.78)
Haemonetics (HAE) Poised on Strong Q2, Optimistic Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:00PM CDT
On Sep 19, 2014, we issued an updated research report on Haemonetics Corporation (HAE).
ICUI: 70.90 (+0.95), ABAX: 51.53 (+1.89), HAE: 38.44 (+0.78), HSP: 54.24 (+2.17)
Insider Trading Alert - TUP, HAE And SNI Traded By Insiders
at The Street - Wed Sep 03, 10:00AM CDT
Stocks with insider trader activity include TUP, HAE and SNI
HAE: 38.44 (+0.78), SNI: 76.53 (-0.29), TUP: 64.08 (+0.20)
Haemonetics to Present at Morgan Stanley's Global Healthcare Conference
PR Newswire - Fri Aug 22, 7:00AM CDT
Haemonetics Corporation (NYSE: HAE) announced today that Brian Concannon, President & CEO, will present at Morgan Stanley's Global Healthcare Conference in New York on September 8th, 2014 at 8:45am Eastern time.
HAE: 38.44 (+0.78), MS: 34.52 (+0.13)
10.1% Return Seen to Date on SmarTrend Haemonetics Call (HAE)
Comtex SmarTrend(R) - Tue Aug 19, 9:30AM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on May 19th, 2014 at $33.61. In approximately 3 months, Haemonetics has returned 10.12% as of today's recent price of $37.01.
HAE: 38.44 (+0.78)
Earnings Look Back: Haemonetics Is Up 0.8% Since Reporting Quarterly Results 2 Weeks Ago (HAE)
Comtex SmarTrend(R) - Mon Aug 18, 7:28AM CDT
Two weeks ago on July 30th, 2014 Haemonetics (NYSE:HAE) reported earnings and analysts, on average, expected earnings of $0.35 on sales of $216.8 million. The company actually reported EPS of $0.38 on sales of $224.5 million, beating EPS estimates by $0.03 and beating revenue estimates by $7.7 million. Since the company's report, shares of Haemonetics have risen from $35.94 to $36.22, representing a gain of 0.8% in the past 19 days.
HAE: 38.44 (+0.78)
Haemonetics Earnings In Retrospect: Up 1.1% in the Last 12 Days (HAE)
Comtex SmarTrend(R) - Mon Aug 11, 7:55AM CDT
12 days ago, on July 30th, 2014, Haemonetics (NYSE:HAE) reported its earnings. Analysts, on average, expected earnings of $0.35 per share on sales of $216.8 million. The company actually reported EPS of $0.38 on sales of $224.5 million, beating EPS estimates by $0.03 and beating revenue estimates by $7.7 million. Since the company's report, shares of Haemonetics have risen from $35.94 to $36.32, representing a gain of 1.1% in the past 12 days.
HAE: 38.44 (+0.78)
Haemonetics Tops Q1 Earnings and Revenues, Guidance Retained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:00PM CDT
Haemonetics' (HAE) shares lost 1.4% to eventually close at $35.57 yesterday, following the huge year over year loss the company experienced in its earnings outcome
ABAX: 51.53 (+1.89), HAE: 38.44 (+0.78), ALR: 40.02 (+1.45), ATRC: 16.36 (+0.16)
Haemonetics Reports 1st Quarter Fiscal 2015 Revenue of $224 Million and Adjusted EPS of $0.38, Affirms Full Fiscal Year Guidance
PR Newswire - Wed Jul 30, 5:00AM CDT
Haemonetics Corporation (NYSE: HAE) today reported first quarter fiscal 2015 revenue of $224.5 million, up 2%. In constant currency, revenue growth was also 2% in the quarter.
HAE: 38.44 (+0.78)
Haemonetics hires Charles J. Dockendorff to board
M2 - Thu Jul 24, 7:02AM CDT
Healthcare company Haemonetics (NYSE:HAE) revealed on Wednesday the election of Charles J. Dockendorff to its board of directors at its Annual Meeting of Stockholders.
HAE: 38.44 (+0.78)
Charles J. Dockendorff Joins Haemonetics Board of Directors
PR Newswire - Wed Jul 23, 10:00AM CDT
Haemonetics Corporation (NYSE: HAE) announced that Charles J. Dockendorff was elected to the Board of Directors at the Company's Annual Meeting of Stockholders today. Mr. Dockendorff, age 59, is Executive Vice President and Chief Financial Officer with Covidien PLC, a position he has held since 1995. He is responsible for Covidien's financial management activities including corporate accounting, tax, treasury, financial planning, investor relations, internal audit and information services, and he oversees the financial leadership of Covidien's three business segments.
HAE: 38.44 (+0.78)
Positive Study Results, Patent Grants, Acquisitions, Patient Enrollment, and Earnings Schedule - Analyst Notes on Synageva, OPKO, bluebird bio, BioDelivery Sciences and Haemonetics
PR Newswire - Thu Jul 03, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Synageva BioPharma Corp. (NASDAQ: GEVA), Opko Health Inc. (NYSE: OPK), bluebird bio Inc. (NASDAQ: BLUE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI) and Haemonetics Corporation (NYSE: HAE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4405-100free.
BDSI: 17.79 (+0.41), BLUE: 41.29 (+1.62), GEVA: 80.06 (+2.93), OPK: 8.39 (unch), HAE: 38.44 (+0.78)
Haemonetics (HAE) is in Overbought Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:55AM CDT
Haemonetics (HAE) is in Overbought Territory: What’s Next?
HAE: 38.44 (+0.78)
Haemonetics Sets Date for First Quarter Fiscal Year 2015 Earnings Release: July 30, 2014
PR Newswire - Mon Jun 30, 7:00AM CDT
Haemonetics Corporation (NYSE: HAE) will announce its earnings for the first quarter of its fiscal year 2015 on Wednesday, July 30, 2014 in a pre-market press release. The Company will host a webcast to discuss and answer questions about the press release at 8:00 am eastern on July 30, 2014.
HAE: 38.44 (+0.78)
Haemonetics Suffers on Dismal Q4, Poor FY15 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 1:55PM CDT
On Jun 27, 2014, we issued an updated research report on Haemonetics Corporation (HAE).
ICUI: 70.90 (+0.95), NURO: 1.69 (+0.05), HAE: 38.44 (+0.78), CRDC: 0.98 (-0.02)
Blood Processing Supplies and Equipment - Global Strategic Business Report 2014: Market Dynamics and Competitive Landscape
M2 - Thu Jun 12, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3njb3/blood_processing) has announced the addition of the "Blood Processing Supplies and Equipment - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. The report profiles 109 companies including many key and niche players such as: - Beckman Coulter, Inc. (US) - Becton, Dickinson and Company (US) - Fresenius Kabi AG (Germany) - Fenwal Inc. (US) - Haemonetics Corp (US) - Immucor Inc. (US) - MacoPharma SA (France) - Terumo Corp. (Japan) - Terumo BCT, Inc. (US) Key Topics Covered: Normal 0 false false false EN-IE X-NONE X-NONE I. Introduction Ii. Executive Summary 1. Industry Overview 2. Market Dynamics 3. Competitive Landscape 4. Blood Components & Derivatives 5. Blood Banking 6. Autologous Blood Transfusions Vis- A-Vis Allogenic Blood Transfusions 7. Risks Associated With Blood Donation And Transfusion 8. Blood Processing Supplies And Equipment: An Overview 9. Product Innovations/Introductions 10. Recent Industry Activity 11. Focus On Select Global Players 12. Global Market Perspective Iii. Market Iv. Competitive Landscape For more information visit http://www.researchandmarkets.com/research/k3...processing About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
HAE: 38.44 (+0.78)
3PEA International and Haemonetics Partner to Integrate PaySign Connect with Haemonetics' Donor Management System
Business Wire - Tue Oct 21, 7:49AM CDT
3PEA International, Inc. (OTCBB:TPNL)(OTCQB:TPNL), a vertically integrated provider of innovative prepaid card programs and processing services for corporate, consumer and government applications, today announced that 3PEA and Haemonetics Corporation (NYSE:HAE) have entered into an agreement whereby 3PEA International will integrate its PaySign(R) Connect prepaid debit card solution with Haemonetics' Donor Management System ("DMS"
. The integration will allow users of the Haemonetics DMS to use the PaySign Connect payment solution for the plasma industry. This partnership will bring together the best of both worlds, the industry leading Haemonetics Donor Management System and 3PEA's PaySign(R) Connect, an intuitive, easy-to-use, fully tokenized payment system tailored to the unique requirements of the plasma collection industry. HAE: 38.44 (+0.78)
Haemonetics Sets Date for Second Quarter Fiscal Year 2015 Earnings Release: November 3, 2014
PR Newswire - Mon Oct 06, 3:00PM CDT
Haemonetics Corporation (NYSE:HAE) will announce its earnings for the second quarter of its fiscal year 2015 on November 3, 2014 in a pre-market press release. The Company will host a webcast to discuss and answer questions about the press release at 8:00 am eastern time on November 3, 2014.
HAE: 38.44 (+0.78)
Perrigo Sells Some Assets to Imago Pharmaceuticals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 3:45PM CDT
Perrigo (PRGO) has out licensed some of its early-stage assets.
BIIB: 321.00 (+5.94), PRGO: 161.33 (+6.33), ABAX: 51.53 (+1.89), HAE: 38.44 (+0.78)
Walgreens Earnings in Line, Alliance Boots Shows Synergy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 9:45AM CDT
Walgreen Co. (WAG) reported adjusted net earnings of 74 cents per share in the fourth quarter of fiscal 2014.
ABAX: 51.53 (+1.89), HAE: 38.44 (+0.78), CVS: 85.55 (+0.36), WAG: 62.96 (+0.13)
Data Intensity Fortifies Track Record of Success in Oracle EBS R12 Implementations and Upgrades
PR Newswire - Tue Sep 23, 8:30AM CDT
Data Intensity, the industry leader in managed and cloud services for Oracle technologies and applications, today announced a significant milestone in the company's rich history of driving implementations and upgrades to Oracle E-Business Suite (EBS) Release 12 (R12) for its global customers. Data Intensity is celebrating the inception of its dedicated application engineering team, established five years ago this month to address the market need for expertise in planning, managing and executing on the most complex Oracle projects. The team also recently completed one of its most challenging upgrades to date for Haemonetics Corp, a global healthcare company that provides innovative blood management solutions. This deployment was one of ten R12 projects Data Intensity has delivered successfully this year, and the most recent of the 70+ R12-focused engagements the team has completed since the technology's release in 2007.
HAE: 38.44 (+0.78)
Haemonetics (HAE) Poised on Strong Q2, Optimistic Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 5:00PM CDT
On Sep 19, 2014, we issued an updated research report on Haemonetics Corporation (HAE).
ICUI: 70.90 (+0.95), ABAX: 51.53 (+1.89), HAE: 38.44 (+0.78), HSP: 54.24 (+2.17)
Insider Trading Alert - TUP, HAE And SNI Traded By Insiders
at The Street - Wed Sep 03, 10:00AM CDT
Stocks with insider trader activity include TUP, HAE and SNI
HAE: 38.44 (+0.78), SNI: 76.53 (-0.29), TUP: 64.08 (+0.20)
Haemonetics to Present at Morgan Stanley's Global Healthcare Conference
PR Newswire - Fri Aug 22, 7:00AM CDT
Haemonetics Corporation (NYSE: HAE) announced today that Brian Concannon, President & CEO, will present at Morgan Stanley's Global Healthcare Conference in New York on September 8th, 2014 at 8:45am Eastern time.
HAE: 38.44 (+0.78), MS: 34.52 (+0.13)
10.1% Return Seen to Date on SmarTrend Haemonetics Call (HAE)
Comtex SmarTrend(R) - Tue Aug 19, 9:30AM CDT
SmarTrend identified an Uptrend for Haemonetics (NYSE:HAE) on May 19th, 2014 at $33.61. In approximately 3 months, Haemonetics has returned 10.12% as of today's recent price of $37.01.
HAE: 38.44 (+0.78)
Earnings Look Back: Haemonetics Is Up 0.8% Since Reporting Quarterly Results 2 Weeks Ago (HAE)
Comtex SmarTrend(R) - Mon Aug 18, 7:28AM CDT
Two weeks ago on July 30th, 2014 Haemonetics (NYSE:HAE) reported earnings and analysts, on average, expected earnings of $0.35 on sales of $216.8 million. The company actually reported EPS of $0.38 on sales of $224.5 million, beating EPS estimates by $0.03 and beating revenue estimates by $7.7 million. Since the company's report, shares of Haemonetics have risen from $35.94 to $36.22, representing a gain of 0.8% in the past 19 days.
HAE: 38.44 (+0.78)
Haemonetics Earnings In Retrospect: Up 1.1% in the Last 12 Days (HAE)
Comtex SmarTrend(R) - Mon Aug 11, 7:55AM CDT
12 days ago, on July 30th, 2014, Haemonetics (NYSE:HAE) reported its earnings. Analysts, on average, expected earnings of $0.35 per share on sales of $216.8 million. The company actually reported EPS of $0.38 on sales of $224.5 million, beating EPS estimates by $0.03 and beating revenue estimates by $7.7 million. Since the company's report, shares of Haemonetics have risen from $35.94 to $36.32, representing a gain of 1.1% in the past 12 days.
HAE: 38.44 (+0.78)
Haemonetics Tops Q1 Earnings and Revenues, Guidance Retained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:00PM CDT
Haemonetics' (HAE) shares lost 1.4% to eventually close at $35.57 yesterday, following the huge year over year loss the company experienced in its earnings outcome
ABAX: 51.53 (+1.89), HAE: 38.44 (+0.78), ALR: 40.02 (+1.45), ATRC: 16.36 (+0.16)
Haemonetics Reports 1st Quarter Fiscal 2015 Revenue of $224 Million and Adjusted EPS of $0.38, Affirms Full Fiscal Year Guidance
PR Newswire - Wed Jul 30, 5:00AM CDT
Haemonetics Corporation (NYSE: HAE) today reported first quarter fiscal 2015 revenue of $224.5 million, up 2%. In constant currency, revenue growth was also 2% in the quarter.
HAE: 38.44 (+0.78)
Haemonetics hires Charles J. Dockendorff to board
M2 - Thu Jul 24, 7:02AM CDT
Healthcare company Haemonetics (NYSE:HAE) revealed on Wednesday the election of Charles J. Dockendorff to its board of directors at its Annual Meeting of Stockholders.
HAE: 38.44 (+0.78)
Charles J. Dockendorff Joins Haemonetics Board of Directors
PR Newswire - Wed Jul 23, 10:00AM CDT
Haemonetics Corporation (NYSE: HAE) announced that Charles J. Dockendorff was elected to the Board of Directors at the Company's Annual Meeting of Stockholders today. Mr. Dockendorff, age 59, is Executive Vice President and Chief Financial Officer with Covidien PLC, a position he has held since 1995. He is responsible for Covidien's financial management activities including corporate accounting, tax, treasury, financial planning, investor relations, internal audit and information services, and he oversees the financial leadership of Covidien's three business segments.
HAE: 38.44 (+0.78)
Positive Study Results, Patent Grants, Acquisitions, Patient Enrollment, and Earnings Schedule - Analyst Notes on Synageva, OPKO, bluebird bio, BioDelivery Sciences and Haemonetics
PR Newswire - Thu Jul 03, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Synageva BioPharma Corp. (NASDAQ: GEVA), Opko Health Inc. (NYSE: OPK), bluebird bio Inc. (NASDAQ: BLUE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI) and Haemonetics Corporation (NYSE: HAE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4405-100free.
BDSI: 17.79 (+0.41), BLUE: 41.29 (+1.62), GEVA: 80.06 (+2.93), OPK: 8.39 (unch), HAE: 38.44 (+0.78)
Haemonetics (HAE) is in Overbought Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:55AM CDT
Haemonetics (HAE) is in Overbought Territory: What’s Next?
HAE: 38.44 (+0.78)
Haemonetics Sets Date for First Quarter Fiscal Year 2015 Earnings Release: July 30, 2014
PR Newswire - Mon Jun 30, 7:00AM CDT
Haemonetics Corporation (NYSE: HAE) will announce its earnings for the first quarter of its fiscal year 2015 on Wednesday, July 30, 2014 in a pre-market press release. The Company will host a webcast to discuss and answer questions about the press release at 8:00 am eastern on July 30, 2014.
HAE: 38.44 (+0.78)
Haemonetics Suffers on Dismal Q4, Poor FY15 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 1:55PM CDT
On Jun 27, 2014, we issued an updated research report on Haemonetics Corporation (HAE).
ICUI: 70.90 (+0.95), NURO: 1.69 (+0.05), HAE: 38.44 (+0.78), CRDC: 0.98 (-0.02)
Blood Processing Supplies and Equipment - Global Strategic Business Report 2014: Market Dynamics and Competitive Landscape
M2 - Thu Jun 12, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k3njb3/blood_processing) has announced the addition of the "Blood Processing Supplies and Equipment - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. The report profiles 109 companies including many key and niche players such as: - Beckman Coulter, Inc. (US) - Becton, Dickinson and Company (US) - Fresenius Kabi AG (Germany) - Fenwal Inc. (US) - Haemonetics Corp (US) - Immucor Inc. (US) - MacoPharma SA (France) - Terumo Corp. (Japan) - Terumo BCT, Inc. (US) Key Topics Covered: Normal 0 false false false EN-IE X-NONE X-NONE I. Introduction Ii. Executive Summary 1. Industry Overview 2. Market Dynamics 3. Competitive Landscape 4. Blood Components & Derivatives 5. Blood Banking 6. Autologous Blood Transfusions Vis- A-Vis Allogenic Blood Transfusions 7. Risks Associated With Blood Donation And Transfusion 8. Blood Processing Supplies And Equipment: An Overview 9. Product Innovations/Introductions 10. Recent Industry Activity 11. Focus On Select Global Players 12. Global Market Perspective Iii. Market Iv. Competitive Landscape For more information visit http://www.researchandmarkets.com/research/k3...processing About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
HAE: 38.44 (+0.78)
